Search research articles
Contact Us
Filters
Showing results (221-230 of 442) with videos related to
Page
of 45
Sort By:
Journal for Immunotherapy of Cancer
|
December 20, 2017
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
Roman Groisberg, David S Hong, Amini Behrang, et al.
Scientific Reports
|
November 17, 2021
A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies
Siqing Fu, David E Piccioni, Hongtao Liu, et al.
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma
Timothy P DiPeri, Mehmet Demirhan, Daniel D Karp, et al.
Frontiers in Immunology
|
May 2, 2022
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors
James J Harding, Ignacio Garrido-Laguna, Xiaoying Chen, et al.
Cancer Research
|
October 16, 2012
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
Filip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology
|
June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
Mehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2011
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer
David S Hong, Razelle Kurzrock, Yun Oh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 28, 2017
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
Andrew J Wagner, Udai Banerji, Amit Mahipal, et al.
Oncotarget
|
February 26, 2013
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer
Gerald S Falchook, Aung Naing, David S Hong, et al.
Investigational New Drugs
|
May 21, 2015
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver
Rabih Said, Razelle Kurzrock, Aung Naing, et al.
Page
of 45
Search research articles
Search
Showing results (221-230 of 442) with videos related to
Sort By:
Page
of 45
Journal for Immunotherapy of Cancer
|
December 20, 2017
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
Roman Groisberg, David S Hong, Amini Behrang, et al.
Scientific Reports
|
November 17, 2021
A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies
Siqing Fu, David E Piccioni, Hongtao Liu, et al.
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma
Timothy P DiPeri, Mehmet Demirhan, Daniel D Karp, et al.
Frontiers in Immunology
|
May 2, 2022
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors
James J Harding, Ignacio Garrido-Laguna, Xiaoying Chen, et al.
Cancer Research
|
October 16, 2012
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
Filip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology
|
June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
Mehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2011
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer
David S Hong, Razelle Kurzrock, Yun Oh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 28, 2017
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
Andrew J Wagner, Udai Banerji, Amit Mahipal, et al.
Oncotarget
|
February 26, 2013
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer
Gerald S Falchook, Aung Naing, David S Hong, et al.
Investigational New Drugs
|
May 21, 2015
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver
Rabih Said, Razelle Kurzrock, Aung Naing, et al.
Page
of 45